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patient subgroups. For example, in oncology, markers such as KRAS, HER-2/neu and 
BRCA 1,2 are used for prognosis and to direct treatment. To reflect this evolution, 
comparative effectiveness research programme designs and analytical methods 
must be able to detect important treatment effects and outcomes for specific patient 
subgroups. The emergence of patient-centered care adds further complexity to HTA 
data requirements. The systematic collection of patient-reported outcomes (PROs) 
and their application to medicine is far from standard in clinical practice, although 
many clinical trial programmes now include the collection of PROs. For products 
in development, data generation plans must reflect ongoing changes and evolving 
complexities. We will review the growing range of methods employed in clinical 
effectiveness research, and show how personalised medicine and patient outcome 
programmes can strengthen HTA data packages.
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Objectives: Cost-effectiveness Analysis (CEA) and the calculation of the 
Incremental Cost-Effectiveness Ratio (ICER) together with its comparison with a 
threshold such as Gross Domestic Product (GDP)/capita, have long been used to 
assess the value for money of a new intervention compared with a comparator 
that this new intervention precisely seeks to displace. In this paper we show the 
paradoxical increase in cost-effective price using data from middle, low and very 
low income settings. MethOds: Using the introduction of rotavirus vaccination 
compared with no-vaccination as the example. We create a theoretical framework 
for calculating the ICER by gradually decreasing the investment for treatment of 
rotavirus related disease (the ‘no-vaccination comparator’) representing different 
countries with different GDP levels and decreasing levels of existing health care 
investment. We compare these results with an analysis of cost-effectiveness using 
real data from 9 countries representing a range of different GDP levels. Results: 
The theoretical framework works well in situations where the GDP/capita exceeds 
$10,000 – as expected the cost-effective price decreases with a decrease in the 
GDP/capita. Below this the scant investment in health care infrastructure, thereby 
reducing potential cost-offsets, coupled with the significant increase in the poten-
tial effect gain, results in a much wider margin between a cost-neutral and cost-
effective price that could effectively be set using this approach. cOnclusiOns: 
Although Cost-Effectiveness Analysis is widely used to assess the value for money 
of a new intervention for a particular price, we would argue that where investment 
in health care is low and disease burden is high, the use of CEA leads to paradoxes 
in price-setting.
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Objectives: Presents a reengineering process of the distribution of drugs into the 
hospital, analyzing all the options available in the market, and looking for alterna-
tive solutions that may be more cost-effective. MethOd: The processes and sub-
processes in the cycle from prescribing, distribution, and drug administration, are 
defined and discussed based on studies of medication errors (ME). The differential 
analysis is performed on the subprocesses. As technique for finding creative solu-
tions (new cost-effective alternatives) apply the Theory of Constraints (TOC), and the 
TRIZ methodology. Results: Since patient safety can distinguish four processes: 
prescription (about 40% of ME), transcription, distribution (about 10% each), and 
administration (about 40% of ME). In the administration, avoided ME before they 
reach the patient are minimal (only 2%). In the prescription/transcription there 
are 4 options: manual prescription, preprinted sheets, electronic prescription, 
and assisted prescription. In the distribution has 3 options: clasical SUD, filling 
carts using automated carousels, and automated dispensing systems (ADS). For 
administration there are other 3 options: manual record, electronic registration, and 
registration across the barcode. The most expensive option would be the introduc-
tion of ADS in all plants (1.4 million€ for a hospital of 280 beds). But these teams 
only reduces errors about 10% of all ME. Applying the TOC and TRIZ, investment in 
electronic prescribing, and administration with barcodes is the most cost-effective. 
Dose-day (sending medication for one day but not rated by patient) could be the 
most efficient system by simplifying processes. The error difference between Dose-
day, and SDU can be annulled by the advantages of the assisted prescription, and 
administration with barcode cOnclusiOns: It is surprising to invest large sums in 
improving distribution processes (ADS) - where the fewest mistakes occurs - instead 
of prescribing and administration. The dose-day with barcode administration would 
be the most cost-effective theoretical-model.
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Objectives: The R&D costs of a new drug approximate $1.3 billion and are increas-
ing due partly to regulatory hurdles and development costs. There is a need for 
smarter investments, which consider the requirements of regulatory bodies, 
increasing the chances of securing market access and high return on investment. We 
describe how health economic methods could support capital investment decisions 
in funding, valuing and bringing new pharmaceuticals to market. MethOds: A lit-
erature review was performed on health economic and capital investment methods. 
The different analyses were mapped to the commercial roadmap and R&D pipeline 
the near future, and similar levels of efficacy and acquisition cost as key compara-
tors In rare circumstances conducting an STA may not be cost-effective. It is possible 
that this can be predicted early in the STA process and we propose criteria to aid in 
this decision. When these criteria are met the possibility of “unreferring” the topic 
is likely to be the most cost-effective option.
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Objectives: To call attention to the problems resulting from the National Institute 
for Health and Care Excellence’s (NICE) recent revision to their methods guidance 
on discounting, which recommends applying a lower discount rate than the refer-
ence case rate in selected cases. MethOds: NICE’s reference case discount rate for 
costs and health effects is 3.5%. In 2011 NICE amended their economic appraisal 
guidelines recommending differential discounting of costs and health effects at 
3.5% and 1.5% respectively in selected cases. A recently published article in Value in 
Health criticised this amendment on a number of grounds, including ambiguity over 
what are the eligible selected cases; the lack of rationale for selective application 
of differential discounting; the apparent inconsistencies that unjustified selective 
application give rise to; and, the size of the differential between the two discount 
rates. In April 2013 NICE published a comprehensive revision of their methods guide-
lines, in which equal discounting of costs and effects at 1.5% in selected cases is 
now recommended. Results: While NICE’s new 2013 guidance no longer includes 
an unjustified differential between the discount rate on costs and health effects, 
it still recommends the application of lower discount rates in selected cases. The 
revised guidance still offers no rationale for such selective application of lower dis-
count rates. This means that many of problems described in the recently published 
critique of the 2011 amendment still apply to the new 2013 guidance, including a 
particularly worrying potential for age discrimination. cOnclusiOns: NICE’s selec-
tive application of lower discount rates in certain cases is not justified and leads to 
inconsistencies in the appraisal of different interventions. NICE is urged to again 
revise their discounting guidance, this time ensuring all interventions are treated 
equally and are subject to the same discount rates.
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Most cost-effectiveness models for evaluation of cancer care compare interventions 
within a single treatment line. However, to investigate the full impact of a new 
treatment, also downstream effects must be taken into account. Furthermore, most 
models are based on observed clinical states, whilst these observations depend on 
the timing of examinations and the choice of diagnostic test. To evaluate the poten-
tial of new treatments and diagnostics, the underlying disease process needs to be 
modeled including the interaction with diagnostics and treatment.Objectives: 
To build a flexible framework for a disease model, that simulates cancer progres-
sion to obtain clinical, patient and economic outcomes, while taking diagnostics 
treatment pathways and surveillance schedules into account . MethOds: The 
modeling framework discerns two levels to describe disease progression, the level 
of the patient and the tumor. At the patient level, an individual is characterized 
by clinical states; “primary tumor only”, “local recurrence”, “regional recurrence”, 
“distant metastasis, stable”, “distant metastasis, progressing” and “death”. The 
clinical state is derived from disease development at the tumor level. Seven tumor 
growth states are defined: “absent tumor”, “dormant tumor”, “micro tumor”, “small 
macro tumor”, “medium macro tumor”, “large macro tumor”, “symptomatic tumor”. 
Melanoma progression was used as a case study. The model simulates, in parallel, 
11 possible tumor sites, ranging from “local” to “regional” and “distant metastatic” 
locations. Sites were chosen because they are associated with different treatment 
and prognosis. The disease model is complemented with a treatment and surveil-
lance module. In this module, treatment choices in each of the clinical states are 
specified. Treatment choice may depend on patient and tumor features, and subse-
quently influences rate of transitioning between tumor growth states. For surveil-
lance, timing of surveillance visits, techniques used and their detection rate(s) are 
specified. cOnclusiOns: The proposed framework provides a flexible and widely 
applicable cancer modeling design.
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Defining value and generating innovation in health care relies increasingly on real 
world evidence. Consequently, there is an ongoing evolution in the data needs for 
health technology assessment (HTA). Three key elements of data generation are 
comparative effectiveness, personalised medicine and patient-centred outcomes. 
Integrating these three to support synthesis via systematic reviews, meta-analyses 
and modeling is necessary to maximise value and drive innovation. Effectiveness 
is not just about reduced morbidity and mortality. It now covers quality of life, 
patient satisfaction, intermediate endpoints, and screening/diagnosis/monitoring. 
Additionally, there is a shift away from effectiveness versus placebo to compara-
tive effectiveness versus other technologies or standards of care in the real world, 
focusing on the effect on health outcomes in defined patient populations based on 
ethnicity, comorbidities or age. Personalised medicine signals another shift of focus 
away from broad, homogenous patient populations to small, more-or-less defined 
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data on the general population. Specific examples of large systematic reviews con-
ducted for estimating food safety accounting for population variability and inter-
actions between food contaminants and drugs are also presented. Details on the 
model-based meta-analyses of such safety data are described and discussed for the 
purpose of regulator’s decision making. Systematic reviews have been to the context 
of food and nutritional epidemiology requiring more stringent quality assessment 
and more advanced management of variability. This resulted in a Bayesian random 
effect model accounting for population variability. Metabolic interactions between 
food and drugs were evidenced and variability metrics could be explicated in terms of 
“uncertainty factors” to be used by the food regulators to assess safety limits for food 
ingredients, contaminants or drugs and their combined use. Food regulator in EU is 
aligning and even sometimes anticipating drug regulators in terms of evidence-based 
safety assessment in the real life. Common tools for model-based evidence synthesis 
can be applied to quantify safety signals and interaction in the general population.
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Objectives: Cost-effectiveness analyses (CEA) have become widely used in several 
pathologies. Currently, new CEA studies comparing active vs control treatment have 
been incorporated each year. For this reason, the combination of CEA studies could 
give a more consistent and accurate estimate of an intervention’s efficiency than 
one study alone. The aim of study was to develop a new method to do compara-
tive efficiency research (COMER) based in individual patient data. MethOds: After, 
adjusted the marginal distribution and copula distribution of a hypothetical cohort, 
we stated the parameters and distribution estimated like our unknown theoretical 
distribution. We conducted an iterative analysis of a random Frank Copula distribu-
tion with a different range of sample size. We performed a comparison between 
samples and theoretical distribution in terms of incremental cost-effectiveness ratio 
(ICER), incremental monetary benefit(IMB) fixed a threshold (k= 20.000 monetary 
units) and goodness of fit for Frank copula, assuming a tolerance. Results: The 
Theoretical distribution fixed, showed a cost of 604.34 monetary units for active and 
516.12 monetary units for control, and a utilities of 0.529 for active and 0.492 for 
control. ICER for theoretical cohort was 2,380 monetary units per quality-adjusted 
life year gained and IMB was 653. With a tolerance of 500 monetary units for ICER 
and 50 monetary units for IMB, only 15.52% of simulations were near the theoretical 
ICER and only 6.12% of IMB. The amount of individual patients simulated was more 
than 500 patients per treatment to fit Frank Copula. cOnclusiOns: Preliminary 
results showed that COMER based in individual patients’ data could allow decision 
maker to know real add-value of a new intervention.
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Benefits of diagnostics tests generally centre on test accuracy measures. However, 
additional benefits of diagnostics may include: reduced laboratory time, reduced time 
to results and increases in the capacity of a laboratory to deliver more tests. New tech-
nological developments, such as high throughput sequencing (HTS) are challenging the 
current methods used in establishing the case for the introduction into clinical practice 
terms of economic impact. This is evident in the case study developed here examining 
BRCA1/2 genetic testing in providing information on the risk of development of breast 
cancer. Current BRCA1/2 testing technologies are limited by long (up to one-year) turna-
round times, which together with limited resources to increase the volume of tests 
and associated genetic counselling, has driven the use of a ‘risk threshold’ to target 
women eligible for testing. HTS offers the opportunity of decreased turnaround time 
and increased volume of BRCA1/2 tests, which will impact on the benefits and costs 
associated with the diagnostic service. Systematic reviews have identified Markov-type 
models as the dominant modeling methodology for the assessment of genetic testing. 
We propose that discrete event simulation (DES) is the appropriate model type to quan-
tify the economic impact of HTS BRCA1/2 testing as it allows evaluation of the impact 
of capacity constraints and increased turnaround time on the costs and benefits of 
this new diagnostic technology. Importantly, DES also allows for the assessment of 
structural uncertainty by considering changes in patient pathways when using a new 
diagnostic technology. While DES may be the most appropriate modeling methodology 
in assessing the economic impact of novel genetic tests; typically the type of data and 
information required to popuate these models in lacking. We conclude by highlighting 
the type of data required to both population appropriate models and to adequately 
assess the economic impact of these novel genetic tests.
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In this paper, we critically evaulated analytical design of health technology assess-
ment methodologies, particularly related to sensitivity analyses and willingness-
to-pay thresholds. To this end, we have used two studies: the first one analyzing 
cost-effectiveness of a human papillomavirus vaccination of boys at age 12 against 
oropharyngeal carcinoma and anogenital warts and the second one examining 
cost-effectiveness of a universal programme of vaccinating children against pneu-
mococcal disease. We have shown – as expected – that the impact of variation of 
parameters can be substantial, however, outcomes of sensitivity analyses are often 
understated both by marketing authorization holders and authorities. Few would 
of a biopharmaceutical company. An approach based on real options valuation 
model was proposed to support investment and market decisions and to predict the 
potential net present value (NPV) of a drug. The conceptual structure of the model 
was face-validated by health economic and valuation experts. Results: A deci-
sion-tree based valuation method, populated partially by information from health 
economic tools, was adopted to analyse and clearly communicate R&D investment 
opportunities, to capture management flexibility and to improve strategic thinking. 
A feedback loop can be built into the model to analyse resiliency to assumption 
changes. In early phases, headroom and multi-criteria decision analyses indicate 
the likelihood of an investment being cost-effective. Phase I and II trials provide 
early evidence on drug efficacy and tolerability and initial cost estimates. Based 
on value of information, cost-effectiveness and budget impact models, only drugs 
deemed to meet authority requirements would be selected. Market intelligence 
and uncertainties and clinical success probability further enable identification of 
the optimal portfolio containing drug candidates that maximize NPV for given risk 
levels. cOnclusiOns: Health economic methods are commonly applied during 
late stage development, but if implemented alongside capital investment tools from 
earliest R&D stages they could increase the likelihood of selecting the right products 
to compose an effective investment portfolio.
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Cancer treatment effectiveness is often quantified by analyzing time from treat-
ment initiation to the occurrence of a particular event. Very commonly studies 
report data on overall survival (OS), where the event is death from any cause, and on 
progression-free survival (PFS), where the event is death from any cause or disease 
progression, whichever occurred first. Both OS and PFS can inform decision making. 
Separate meta-analyses of OS and of PFS data ignore the correlation between the 
outcomes. We introduce a method for the joint meta-analysis of OS and PFS that is 
based on a tri-state transition model with time-varying hazard rates modeled with 
fractional polynomials. In English, we assume that, at any time, patients can be in 
one of three health states: “alive but not progressed”, “alive and progressed”, and 
“dead”. PFS corresponds to time spent in the first state, and OS to time spent in the 
two alive states. The proposed approach allows the joint network meta-analysis 
of OS and PFS, relaxes the proportional hazards assumption, extends to a network 
of more than two treatments, and simplifies the parameterization of decision and 
cost-effectiveness analyses. The data needed to run these analyses can be extracted 
directly from published survival curves. We demonstrate use by applying the meth-
odology to a network of trials for the treatment of non-small cell lung cancer.
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bAckgROund: The global economic crisis imposes severe restrictions on budgets 
allocated to health care. Innovative technologies in medicine may improve patient 
outcomes but such improvements come at a substantial cost, thus limiting the num-
ber of patients that may benefit from them. According to current cost-effectiveness 
analyses (CEA), most innovative interventions are associated with a higher efficacy 
and higher costs compared with the standard of care. These analyses do not account 
for the budget impact associated with implementing the interventions on all eligible 
patients. Even when a new intervention is highly cost-effective, health care systems 
may not be able to adopt it due to substantial budgetary impacts. Implementing a 
substantially lower-cost intervention to a substantially wider population, accept-
ing inferior per-patient outcomes, may improve overall health outcomes under a 
restricted budget. Objectives: Develop an innovative health technology assess-
ment (HTA) model that combines CEA and budget-impact analyses, thus enabling to 
compare the impact of intervention alternatives on the entire intended use popula-
tion, under a pre-specified budget constraint. MethOds: We identified the follow-
ing steps to be included in the model formulation: 1) Define the intended use and the 
target population. 2) Define two or more interventions, one of them at higher cost 
and better per-patient outcome, and the second with lower cost and inferior per-
patient outcome. 3) Forecast the diffusion of the alternatives into the entire intended 
use population, under a pre-defined budget, in order to estimate the treated and 
untreated populations. 4) Calculate the clinical impact of each alternative on the 
treated population. 5) Calculate the clinical impact of no therapy on the untreated 
population 6) Compare the aggregated clinical impact of each alternative on the 
entire intended use population – both treated and untreated. Using the proposed 
population-based model may result in improved health care outcomes, especially 
in times of economic downturn and austerity.
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Evidence-based medicine has emerged as the bottom line of Health Technology 
Assessments for drug evaluations. Over the last decade, evidence-based assessment 
of food and nutritional products has accelerated. Specific quantitative tools to syn-
thetize evidence have been increasingly developed, and used for decision support. 
This work aims at highlighting the critical role of systematic reviews and model-based 
evidence synthesis in the field of food sciences and nutrition, especially with the view 
of safety assessment. To first set the scene of food assessment in Europe, the latest 
Guidelines on Systematic Reviews published by the European Food Safety Authority 
(EFSA) (EFSA, 2010) are described with the approach on how to handle observational 
